A comprehensive evaluation of available evidence suggests that the extensive list of side effects linked to statin use is significantly exaggerated. This finding is prompting calls for an update to the medication’s packaging, driven by concerns that warnings about unsubstantiated side effects may deter individuals from using these life-saving drugs.
Christine Reith from the University of Oxford stated at a press briefing on February 3rd, “We can now be confident that statins do not cause the vast majority of medical issues listed as potential side effects in statin patient information leaflets.”
Statins are widely prescribed, cost-effective medications that effectively lower cholesterol levels, thereby substantially reducing the risk of heart attacks and strokes. However, long-standing apprehension has surrounded their purported side effects, most notably muscle pain. This concern persists despite a 2022 study indicating that statins are rarely the cause of such symptoms.
Reith further explained, “Unfortunately, ongoing confusion and concern—not just in patients, but also many doctors regarding potential statin side effects—mean that many people are not willing to start statins or stop [taking] them.”
In response, Reith and her colleagues undertook an examination of side effects commonly cited on statin labels. These include symptoms like dizziness, fatigue, memory loss, and headaches, which typically arise from case reports and observational studies. Their research specifically excluded investigations into muscle pain or weakness, as well as the potential increased risk of diabetes, an area flagged with a minor risk in a prior analysis.
For their study, the researchers analyzed 19 randomized controlled trials that involved 120,000 participants. These individuals were monitored for an average of 4.5 years to assess the effects of five commonly prescribed statins when compared against a placebo. The trials examined 66 different side effects.
The analysis revealed that for most of the documented side effects, statins did not appear to be the causative agent. The incidence rates for these effects were similar in the groups receiving a placebo. Jeffrey Berger at New York University Langone Health suggests that these perceived side effects might be attributed to the nocebo effect, where an individual’s expectation of harm leads to the experience of negative symptoms.
The research did identify that statins can legitimately increase the risk of a limited number of side effects, including elevated protein levels in urine, limb swelling, and alterations in liver function. However, these increases were not significant enough to be considered harmful. “This allows us to be confident in saying that the benefits of statins really do significantly outweigh their risks,” Reith affirmed.
Karol Watson of the University of California, Los Angeles, advocates for drug regulators to update statin labels. She suggests that labels could differentiate between side effects demonstrably caused by statins and those that occur at comparable rates among individuals taking a placebo.
However, such regulatory changes are often not swift. For instance, the UK’s Medicines and Healthcare Products Regulatory Agency only recommended in January 2026 that statin labels be updated to include descriptions of muscle weakness and pain as potential side effects.
In the interim, clinicians can utilize these study findings to provide reassurance to both current statin users and those who could benefit from the medication. “It’s not about telling people that they’re crazy, that they’re wrong or you don’t have a side effect, it’s about educating them to change their expectations and help them,” Berger commented.
Watson expressed hope that this review will help resolve the ongoing debate surrounding statin side effects. “The focus of future work should shift away from asking whether statins generally cause these symptoms – we already have this answer,” she stated. Instead, she elaborated, future research should concentrate on identifying specific individuals who may be susceptible to certain statin-related side effects, particularly those with multiple health conditions, and understanding the underlying reasons in real-world contexts.
Journal reference: The Lancet DOI: 10.1016/S0140-6736(25)01578-8